US-based Becton, Dickinson and Co (BD) has announced seven underwritten public offerings of notes to raise $10.463bn.
The notes carry interest rates of 0.368% (due June 2019), 2.133% (due June 2019), and 2.404% (due June 2020). They also have rates of 2.894% (due June 2022), floating rate (due June 2022), 3.363% (due June 2024), 3.700% (due June 2027), and 4.669% (due June 2047).
EarLens Corp has announced the private placement of Series C preferred stock in order to raise $73m.
The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities.
The UK-based biopharmaceutical company AstraZeneca plc has announced three public offerings of senior notes, including floating rate senior notes to raise gross proceeds of $2bn.
The notes bear interest rates of 2.375% and 3.125%, which are due to mature in 2022 and 2027, respectively.
AstraZeneca plans to use the funds for general corporate purposes.
As part of the agreement, 2bPrecise will incorporate the new protocols to measure results in patients affected with cardiovascular genetic disease.
2bPrecise is a provider of cloud-based precision medicine platform and is based in the US.
Trice Medical Inc has announced the raising of $19.3m in a series C venture financing round.
The US-based orthopaedic diagnostics devices developer plans to use the funds to expand its presence in the US market.